What is "lerdelimumab"

n. A human monoclonal antibody and immunosuppressive drug developed to reduce scarring after glaucoma drainage surgery.

Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug developed to reduce scarring after glaucoma drainage surgery. Development was stopped in late 2005 after unsuccessful trial results.